Yap J, Hayashida K, Lee MKY, Stub D, Hon JKF, Ho KW, Lo S, Seth A, Kim HS, Wongpraparut N, Nguyen QN, Dy TC, Chandavimol M, Ewe SH, Yin WH, Lee YT, Tay EL, Poon K, Chen M, Chui A, Lam SC, Rao RS, Izumo M, Nair R, Tang GH, Tabata M, Yahaya SA, Sin KY, Park DW, Wang J, and Chieh JTW
Transcatheter aortic valve implantation (TAVI) has been established as an effective treatment modality in patients with severe aortic stenosis (AS) and the uptake of TAVI is rapidly growing in the Asia-Pacific region. However, there exist a heterogeneity in the management of aortic stenosis and the use of TAVI among countries in the region. Reasons for these differences include anatomic variations, disparity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of AS in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group, including a multidisciplinary group of general and interventional cardiologists, cardiac surgeons, imaging specialists, developed a position statement on the recommendations for TAVI in the management of aortic stenosis. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of "agree" or "neutral." The resulting 28 statements provide guidance for clinical practitioners in the region on the use of TAVI in the treatment of patients with aortic stenosis., Competing Interests: JY received speaker's honoraria from Abbott, Biosensors, Biotronik, Boston Scientific, Edwards, GE Healthcare, Johnson & Johnson, Kaneka, Medtronic and Terumo; is a proctor for Edwards Lifesciences and Medtronic; and is on the editorial board of the Journal of Asian Pacific Society of Cardiology; this did not influence peer review. KH is a proctor for Medtronic, Edwards Lifesciences and Abbott. KWH has received speaker fees from Medtronic, Edwards Lifesciences and Abbott Vascular. SL has received honoraria and travel support from Abbott, Bayer, Bioexcel, Boehringer Ingelheim, Boston Scientific, Medtronic and Pfizer. AS is a member of the advisory board and speaker’s bureau, and proctor for Medtronic; and is a member of the speaker’s bureau and proctor for Meril Lifesciences and Boston Scientific. QNN is on the editorial board of Journal of Asian Pacific Society of Cardiology; this did not influence acceptance. TCD is a proctor for Medtronic. MC is a proctor for Edwards Lifesciences, Boston Scientific and Abbott. SHE has received consultant and speaker fees from Abbott Vascular, Philips and GE. WHY is a proctor for Medtronic, Edwards, Boston Scientific, and Abbott. YTL is a proctor for Medtronic, Edwards Lifesciences and Abbott. ELT is a proctor for Medtronic, Edwards Lifesciences and Abbott. GHLT has received speaker’s honoraria and served as a physician proctor, consultant, advisory board member, TAVR publications committee member, APOLLO trial screening committee member and IMPACT MR steering committee member for Medtronic; has received speaker’s honoraria and served as a physician proctor, consultant, advisory board member and TRILUMINATE trial anatomic eligibility and publications committee member for Abbott Structural Heart; has served as an advisory board member for Boston Scientific and JenaValve; a consultant and physician screening committee member for Shockwave Medical; a consultant for NeoChord, Peija Medical and Shenqi Medical Technology; and has received speaker’s honoraria from Siemens Healthineers. JWCT reports honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AstraZeneca, Roche, Otsuka, Terumo and Abbott Vascular; consulting fees from Elixir, CSL Behring and Radcliffe Publishing; and is on the editorial board of Journal of Asian Pacific Society of Cardiology; this did not influence acceptance. All other authors have no conflicts of interest to declare., (© 2024 The Authors.)